Blood Preparation Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Blood Preparation Market 

5.1. COVID-19 Landscape: Blood Preparation Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Blood Preparation Market, By Product

8.1. Blood Preparation Market Revenue and Volume Forecast, by Product, 2024-2033

8.1.1. Whole blood

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Blood components

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Blood derivatives

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Blood Preparation Market, By Antithrombotic and Anticoagulants Type

9.1. Blood Preparation Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type, 2024-2033

9.1.1. Platelet aggregation inhibitors

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Fibrinolytics

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Anticoagulants

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Blood Preparation Market, By Application 

10.1. Blood Preparation Market Revenue and Volume Forecast, by Application, 2024-2033

10.1.1. Thrombocytosis

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Renal impairment

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Pulmonary embolism

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

10.1.4. Angina blood vessel complications

10.1.4.1. Market Revenue and Volume Forecast (2021-2033)

10.1.5. Others

10.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Blood Preparation Market, By End User 

11.1. Blood Preparation Market Revenue and Volume Forecast, by End User, 2024-2033

11.1.1. Clinics

11.1.1.1. Market Revenue and Volume Forecast (2021-2033)

11.1.2. Hospitals

11.1.2.1. Market Revenue and Volume Forecast (2021-2033)

11.1.3. Diagnostic centers

11.1.3.1. Market Revenue and Volume Forecast (2021-2033)

11.1.4. Research labs

11.1.4.1. Market Revenue and Volume Forecast (2021-2033)

11.1.5. Blood banks

11.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 12. Global Blood Preparation Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.1.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.1.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.1.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.1.5.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.1.5.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.1.5.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.1.6.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.1.6.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.1.6.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.2.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.2.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.2.5.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.2.5.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.5.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.2.6.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.2.6.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.6.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.2.7.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.2.7.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.7.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.2.8.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.2.8.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.8.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.3.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.3.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.3.5.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.3.5.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.5.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.3.6.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.3.6.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.6.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.3.7.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.3.7.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.7.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.3.8.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.3.8.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.8.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.4.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.4.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.4.5.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.4.5.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.5.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.4.6.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.4.6.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.6.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.4.7.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.4.7.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.7.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.4.8.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.4.8.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.8.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.5.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.5.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.5.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.5.5.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.5.5.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.5.5.4. Market Revenue and Volume Forecast, by End User (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)

12.5.6.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2021-2033)

12.5.6.3. Market Revenue and Volume Forecast, by Application (2021-2033)

12.5.6.4. Market Revenue and Volume Forecast, by End User (2021-2033)

Chapter 13. Company Profiles

13.1. AstraZeneca plc

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Baxter International Inc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Bristol-Myers Squibb Company

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Celgene Corp.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. GlaxoSmithKline PLC

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Leo Pharma A/S

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Pfizer, Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Portola Pharmaceuticals, Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Sanofi

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Shandong East Chemical Industry Co.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms